Meanwhile, CD4+ T cells activated by tumor antigens presented on MHC class II molecules enhance the activity of CD8+ T cells, promote MHC class I expression on tumor cells, stimulate cytotoxicity of myeloid cells, and finally contribute to the targeted destruction of tumor cells [41,42]. This evidence concerns the gene CD8A and neoplasm.